Back to Search
Start Over
Bimekizumab for the treatment of psoriatic arthritis.
- Source :
- Expert Review of Clinical Immunology; Feb2024, Vol. 20 Issue 2, p155-168, 14p
- Publication Year :
- 2024
-
Abstract
- Interleukin (IL)-17A and IL-17F have overlapping roles in pro-inflammatory signaling and have been implicated in the pathogenesis of psoriatic disease. Bimekizumab is the first human monoclonal antibody to selectively inhibit IL-17F in addition to IL-17A. Bimekizumab has been studied in several phase II/III trials and has been approved for the treatment of patients with psoriatic arthritis (PsA) in the EU and UK. A literature search identified clinical trials examining the efficacy and safety of bimekizumab for PsA, which were critically appraised. Clinical trials of bimekizumab in PsA have demonstrated rapid and sustained treatment responses and depth of response across the multiple disease domains. High levels of efficacy were sustained to 152 weeks in phase IIb trials, and to 52 weeks in phase III trials. Bimekizumab was generally well tolerated. As expected, due to the role of IL-17 in the immune response to fungal pathogens, there was an increase in mild-to-moderate, localized fungal infections with bimekizumab treatment, very few of which led to discontinuation. Studies over longer time periods, with relevant comparators from the IL-17A inhibitor class, and real-world data will be important to further define the role of bimekizumab among currently available treatments for PsA. [ABSTRACT FROM AUTHOR]
- Subjects :
- CLINICAL trials
MYCOSES
MONOCLONAL antibodies
PARACOCCIDIOIDOMYCOSIS
Subjects
Details
- Language :
- English
- ISSN :
- 1744666X
- Volume :
- 20
- Issue :
- 2
- Database :
- Complementary Index
- Journal :
- Expert Review of Clinical Immunology
- Publication Type :
- Academic Journal
- Accession number :
- 174908573
- Full Text :
- https://doi.org/10.1080/1744666X.2023.2277266